Tascenso ODT (Fingolimod Lauryl Sulfate) Patent Expiration, LOE Window & CMS Spending

Tascenso ODT (Fingolimod Lauryl Sulfate) by Cycle: FDA Orange Book LOE 2036-01-19, 0 AB generics, $3.9M 2024 CMS Part D & Medicaid spend, and $9,741 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCycle
FDA Application & PathwayN214962 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2036-01-19
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$3.9M
2024 Medicare Part D Spend$1.9M
2024 Medicaid Spend$2.0M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($9,741 intro WAC)